Last reviewed · How we verify

DTaP-IPV//PRP~T and Hepatitis B vaccine

Sanofi Pasteur, a Sanofi Company · Phase 3 active Biologic

DTaP-IPV//PRP~T and Hepatitis B vaccine is a Combination vaccine Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 3 development for Prevention of diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b infection, and hepatitis B in infants and children. Also known as: Pentaxim™, Euvax B®.

This combination vaccine stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b, and hepatitis B.

This combination vaccine stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b, and hepatitis B. Used for Prevention of diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b infection, and hepatitis B in infants and children.

At a glance

Generic nameDTaP-IPV//PRP~T and Hepatitis B vaccine
Also known asPentaxim™, Euvax B®
SponsorSanofi Pasteur, a Sanofi Company
Drug classCombination vaccine
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease Prevention
PhasePhase 3

Mechanism of action

The vaccine contains inactivated toxoids (diphtheria and tetanus), acellular pertussis antigens, inactivated poliovirus, conjugated Haemophilus influenzae type b polysaccharide, and recombinant hepatitis B surface antigen. These components trigger both humoral and cellular immune responses, leading to the production of protective antibodies and memory cells against these six pathogens.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about DTaP-IPV//PRP~T and Hepatitis B vaccine

What is DTaP-IPV//PRP~T and Hepatitis B vaccine?

DTaP-IPV//PRP~T and Hepatitis B vaccine is a Combination vaccine drug developed by Sanofi Pasteur, a Sanofi Company, indicated for Prevention of diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b infection, and hepatitis B in infants and children.

How does DTaP-IPV//PRP~T and Hepatitis B vaccine work?

This combination vaccine stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b, and hepatitis B.

What is DTaP-IPV//PRP~T and Hepatitis B vaccine used for?

DTaP-IPV//PRP~T and Hepatitis B vaccine is indicated for Prevention of diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b infection, and hepatitis B in infants and children.

Who makes DTaP-IPV//PRP~T and Hepatitis B vaccine?

DTaP-IPV//PRP~T and Hepatitis B vaccine is developed by Sanofi Pasteur, a Sanofi Company (see full Sanofi Pasteur, a Sanofi Company pipeline at /company/sanofi).

Is DTaP-IPV//PRP~T and Hepatitis B vaccine also known as anything else?

DTaP-IPV//PRP~T and Hepatitis B vaccine is also known as Pentaxim™, Euvax B®.

What drug class is DTaP-IPV//PRP~T and Hepatitis B vaccine in?

DTaP-IPV//PRP~T and Hepatitis B vaccine belongs to the Combination vaccine class. See all Combination vaccine drugs at /class/combination-vaccine.

What development phase is DTaP-IPV//PRP~T and Hepatitis B vaccine in?

DTaP-IPV//PRP~T and Hepatitis B vaccine is in Phase 3.

What are the side effects of DTaP-IPV//PRP~T and Hepatitis B vaccine?

Common side effects of DTaP-IPV//PRP~T and Hepatitis B vaccine include Injection site pain, redness, or swelling, Fever, Irritability or fussiness, Drowsiness, Loss of appetite.

Related